Co znamená „Vymazat“?
Zvíře mutaci nenese. Nemoc se u něj nerozvine a nepřenese to dál.
Pes Hypomyelinizační polyneuropatie Varianta 1 (HMP1)
The DNA test for Hypomyelinating Polyneuropathy Variant 1 (HMP1) in dogs is essential for early detection of this hereditary neurological disorder. HMP1 affects the myelin sheath, leading to muscle weakness and coordination issues in affected dogs. By identifying carriers and affected dogs through genetic testing, breeders can make informed decisions to prevent the spread of HMP1. This test is especially important for breeds prone to this condition, ensuring healthier future generations. Early diagnosis via the HMP1 DNA test helps veterinarians manage symptoms effectively. Investing in genetic testing promotes responsible breeding and improves overall canine health. Ensure your dog’s well-being with reliable HMP1 DNA testing today.
zkratka: HMP1
Analyzovaná mutace: MTMR2 c.1479+1G>A
dědičnost: Autozomálně recesivní
Akronym
HMP1
Pozorovaná frekvence
Klinická závažnost
Klinická klasifikace
Neurologická onemocnění
Analyzovaná mutace
MTMR2 c.1479+1G>A
Způsob dědičnosti
Autozomálně recesivní
Shrnutí testu:
Hypomyelinating Polyneuropathy Variant 1 (HMP1) is a genetic disorder in dogs that affects the nervous system by impairing the formation of myelin, the protective sheath around nerves. DNA testing for HMP1 helps identify carriers and affected dogs, enabling responsible breeding decisions to reduce disease incidence. This test is particularly important in breeds known to be at risk. Early detection through genetic screening can improve management and care for affected dogs. Overall, DNA testing for HMP1 supports healthier canine populations and informed breeding practices.
Dostupné z balení: Basic
Tento test DNA je součástí balení od našeho balíčku Basic — a je také součástí balení Basic, Standard, Advanced, Complete.
Zobrazit balíčky testů DNA →Vyberte si balení, které nejlépe vyhovuje vaší chovatelské nebo zdravotní strategii vašich zvířat.
Understanding Hypomyelinating Polyneuropathy Variant 1 (HMP1) in Dogs
Hypomyelinating Polyneuropathy Variant 1 (HMP1) is a genetic condition that affects the peripheral nervous system in dogs. This disorder is characterized by a reduction in the myelin sheath, which is essential for the proper functioning of nerve fibers. Myelin is a fatty substance that insulates nerve fibers and facilitates the rapid transmission of electrical signals between the brain and the rest of the body. When myelin is deficient or improperly formed, it can lead to various neurological symptoms.
Symptoms of HMP1
Dogs affected by HMP1 may exhibit a range of neurological symptoms, which typically include weakness, difficulty in coordination, and loss of muscle tone. These symptoms can vary in severity and may progressively worsen over time. Affected dogs may also display an unsteady gait, difficulty in climbing stairs, or challenges in performing routine activities such as running or jumping.
Genetic Basis of HMP1
The genetic underpinnings of Hypomyelinating Polyneuropathy Variant 1 are linked to specific mutations in genes responsible for the synthesis and maintenance of myelin. These mutations disrupt the normal development and function of Schwann cells, which are the cells that produce myelin in the peripheral nervous system. As a result, the myelination process is impaired, leading to the clinical manifestations seen in affected dogs.
Importance of DNA Testing for HMP1
DNA testing for Hypomyelinating Polyneuropathy Variant 1 is essential for identifying carriers and affected individuals. By understanding the genetic status of a dog, breeders can make informed decisions to minimize the risk of producing offspring with this condition. Early detection can also aid in managing the symptoms and providing appropriate care for affected dogs, improving their quality of life.
Možnosti řízení a léčby
While there is no cure for Hypomyelinating Polyneuropathy Variant 1, management strategies can help alleviate symptoms and improve the overall well-being of affected dogs. Supportive care may include physical therapy to enhance mobility and strength, nutritional support to maintain overall health, and regular veterinary check-ups to monitor the progression of the disease. In some cases, medications may be prescribed to manage pain or associated symptoms.
Závěr
Hypomyelinating Polyneuropathy Variant 1 is a significant genetic disorder that impacts the health and mobility of affected dogs. Through DNA testing, breeders and pet owners can gain valuable insights into the genetic status of their dogs, leading to better management practices and informed breeding decisions. Understanding this condition is crucial for improving the lives of dogs affected by HMP1 and ensuring they receive the best possible care.
Plemeno uznané pro zkoušku: Hypomyelinizační polyneuropatie Varianta 1 (HMP1)
- Golden Retriever
🧬 Interpretation of genotypes HMP1
Genotyp
Postavení
🟡 N/N
Nepřenašeč – žádné riziko
🟡 N/HMP1
Přepravce – žádné riziko
❌ HMP1/HMP1
Postižené – v ohrožení
FAQ: porozumění výkladu
Myslí to „přepravce“ vážně?
Ne. Zvíře je obecně zdravé, ale může na něj přenést mutaci potomstvo.
Co když je zvíře „postiženo“?
Nese dvě mutované kopie. Klinické příznaky se očekávají v závislosti na nemoc. Nemělo by se chovat.
Proč jsou rozdíly mezi muži a ženami?
Některé nemoci jsou vázané na pohlaví, takže jejich projev se liší v závislosti na pohlaví zvířete.
Předpovědět potomstvo
N/N (neprenasec)
N/HMP1 (Dopravce)
HMP1/HMP1 (Postižený)
Časté dotazy k testu DNA
Co tento test DNA odhalí?
This DNA test detects the mutation associated with Hypomyelinating Polyneuropathy Variant 1 (HMP1) in order to identify clear, carrier, or at-risk animals.
Proč testovat chovné zvíře?
Testování DNA pomáhá chovatelům plánovat bezpečnější páření a snížit riziko přenosu mutace na potomky.
Jaký je režim dědičnosti tohoto testu?
Režim dědičnosti hlášený pro tento test je autosomálně recesivní.
Která mutace je v tomto testu analyzována?
This test analyses the mutation MTMR2 c.1479+1G>A.
Je nutně postiženo zvíře-přenašeč?
Ne nutně. Interpretace závisí na vzoru dědičnosti a výsledném genotypu.
Reference
Cook Shawna, Hooser Blair N, Williams D Colette, Kortz Gregg, Aleman Monica, Minor Katie, Koziol Jennifer, Friedenberg Steven G, Cullen Jonah N, Shelton G Diane, Ekenstedt Kari J. Canine models of Charcot-Marie-Tooth: MTMR2, MPZ, and SH3TC2 variants in golden retrievers with congenital hypomyelinating polyneuropathy. Neuromuscul Disord. 2023 Aug;33(8):677-691. doi: 10.1016/j.nmd.2023.06.007. Epub 2023 Jun 22.